ArticleEmerging infectious diseases2017
Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China.
Article in Emerging infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04724785 (Real World Study on the Effect of HBV-DNA High-precision Detection Based Anti-viral Regimen Adjustment on Achieving Complete Virologic Response in Patients With Chronic Hepatitis B.), which is not on this map. Cited by 231 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real World Study on the Effect of HBV-DNA High-precision Detection Based Anti-viral Regimen Adjustment on Achieving Complete Virologic Response in Patients With Chronic Hepatitis B.(REACH)
Who cites it
231 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Global prevalence of occult hepatitis B virus infection in HBcAb-positive individuals: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- The prevalence of hepatitis B in Chinese general population from 2018 to 2022: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Pooled it
- Hepatitis B Infection Among Pregnant Women in China: A Systematic Review and Meta-Analysis.Frontiers in public health · 2022Pooled it
- Satisfaction with immunization services and factors associated with satisfaction among guardians of 0-6-year-old children in China: A cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
- Sex Hormone Receptors, HBV Integrations and Their Prognostic Predictive Value Among Hepatocellular Carcinoma Patients.International journal of cancer · 2026Article
- Cancer burden and control in China: landscape, trends and challenges.Nature reviews. Clinical oncology · 2026Review
- Hepatitis B and D burden in Uzbekistan: comprehensive analysis of seroprevalence and risk correlates from a countrywide study.Infectious diseases of poverty · 2026Article
- Spatial and Temporal Disparities in Timely Hepatitis B Birth-Dose Vaccination in Chongqing, China, 2016-2025.Vaccines · 2026Article
- Efficacy of omega-3 fatty acids as a functional food: a multifaceted approach to health reinforcement.Journal of the science of food and agriculture · 2026Review
- Serological epidemiology of hepatitis B virus and vaccine-induced immune dynamics in 58,169 children in Wuhan, China (2019-2025): a cross-sectional analysis of waning immunity and adolescent susceptibility.Virology journal · 2026Article
- Hepatitis B in China: the analysis of mortality and burden of disease trends from 2008 to 2021.BMC public health · 2026Article
- [A real-world study of clinical cure in children with HBeAg-positive chronic hepatitis B from the Guangxi region].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Sex differences in the clinical outcomes of chronic hepatitis B infection among paediatric patients.Biology of sex differences · 2026Article
- Cost-Effectiveness of Risk-Score-Based Surveillance Strategies for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B.Digestive diseases and sciences · 2026Article
- Towards HDV Elimination Through HBV Vaccination: Global Strategies, Challenges, and Policy Gaps.Vaccines · 2026Review
- Real-world efficacy of comprehensive measures against mother-to-child transmission of HBV in south-eastern Jiangsu, China.BMC infectious diseases · 2026Article
- Hepatitis B vaccination in Chinese infants (2002-2006, Guangdong): long-term effectiveness in adulthood and biological features of HBV infection.Frontiers in immunology · 2026Article
- Factors of post-vaccination serological testing coverage among hepatitis B-exposed children in Fujian, China: a population-based cohort study (2021-2023).Frontiers in public health · 2026Article
- Defining success in functional cure for chronic hepatitis B: a nationwide survey of physician benchmarks to guide clinical practice and trial design.Frontiers in public health · 2026Article
171 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
China's hepatitis B virus (HBV) prevention policy has been evaluated through nationally representative serologic surveys conducted in 1992 and 2006. We report results of a 2014 serologic survey and reanalysis of the 1992 and 2006 surveys in the context of program policy. The 2014 survey used a 2-stage sample strategy in which townships were selected from 160 longstanding, nationally representative, county-level disease surveillance points, and persons 1-29 years of age were invited to participate. The 2014 sample size was 31,713; the response rate was 83.3%. Compared with the 1992 pre-recombinant vaccine survey, HBV surface antigen prevalence declined 46% by 2006 and by 52% by 2014. Among children <5 years of age, the decline was 97%. China's HBV prevention program, targeted toward interrupting perinatal transmission, has been highly successful and increasingly effective. However, this progress must be sustained for decades to come, and elimination of HBV transmission will require augmented strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.